Overview

• The ESSENCE Phase III trial demonstrated that semaglutide reduced liver inflammation in 62.9% of patients with MASH, compared to 34.3% in the placebo group.
• Liver fibrosis improved in 36.8% of patients treated with semaglutide versus 22.4% in the placebo group, offering hope for reversing liver scarring.
• Participants on semaglutide experienced an average 10.5% weight loss, suggesting its potential to address underlying metabolic factors driving the disease.
• MASH, a severe form of fatty liver disease affecting 5–7% of U.S. adults, is closely linked to obesity and type 2 diabetes, which were prevalent among trial participants.
• Novo Nordisk has filed for priority FDA review to approve Wegovy for MASH treatment by the end of 2025, potentially expanding its therapeutic applications.